Details of Disease

General Information of Disease (ID: DISPLMYO)

Disease Name HER2-positive breast cancer
Disease Class 2C60-2C6Y: Breast cancer
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DISPLMYO: HER2-positive breast cancer
ICD Code
ICD-11
ICD-11: 2C60-2C65
Disease Identifiers
MONDO ID
MONDO_0006244
UMLS CUI
C1960398
MedGen ID
743175
SNOMED CT ID
427685000

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 4 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Margetuximab DMKEY6S Approved Antibody [1]
Trastuzumab DMZQOUX Approved Antibody [2]
Trastuzumab deruxtecan DMRI010 Approved Antibody drug conjugate [3]
Tucatinib DMBESUA Approved NA [4]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 8 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ICI 118,551 DM3OU54 Phase 3 Small molecular drug [5]
HM-78136B DMZ3BER Phase 2 Small molecular drug [2]
TPIV100 DMB12SG Phase 2 NA [6]
Trastuzumab emtansine DMU1LXS Phase 2 Antibody drug conjugate [5]
ISB 1302 DM1WD8F Phase 1/2 Antibody [7]
ARX788 DMQ9VJW Phase 1 NA [2]
DZD1516 DMEQY4Z Phase 1 Small molecular drug [8]
RG6264 DM97APK Phase 1 NA [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 ClinicalTrials.gov (NCT04197687) TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery. U.S. National Institutes of Health.
7 ClinicalTrials.gov (NCT03983395) Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer. U.S. National Institutes of Health.
8 ClinicalTrials.gov (NCT04509596) DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer. U.S. National Institutes of Health.